Challenges of Catheter Ablation for Atrial Fibrillation in Hemodialysis Patients

The management of atrial fibrillation (AF) in patients on hemodialysis (HD) is fraught with specific challenges owing to the complexities of endstage renal disease (ESRD). Nevertheless, recent improvements in catheter ablation (CA) techniques have significantly enhanced the efficacy and safety of this procedure, thereby incrementally advancing treatment of AF in this high-risk population. Although progress has been made, there is still considerable room for research and development to address the ongoing issues in this area.

Article p 1057

Hemorrhagic Complications

Hemorrhagic complications are a critical concern in patients with ESRD undergoing CA, primarily because of their increased susceptibility to bleeding mediated by platelet hyporeactivity.¹ This heightened risk is influenced by factors such as inherent vascular fragility and the use of anticoagulation therapy in the perioperative period, which is a necessary but complex aspect of care.² Although anticoagulation is managed individually, the primary focus in this context is on the patient’s inherent tendency towards bleeding. Improvements in procedural techniques have been instrumental in mitigating this risk; however, management of bleeding remains a central concern in providing safe and effective CA therapy to HD patients (Figure).

Figure.

Challenges and concerns regarding catheter ablation for atrial fibrillation (AF) in patients undergoing hemodialysis. PVI, pulmonary vein isolation.

Anticoagulation Therapy Management

Managing anticoagulation in patients undergoing CA for AF remains a nuanced challenge. Thrombotic episodes increase in patients with ESRD because of platelet activation.¹ A standardized approach has yet to be established, with current practices largely involving individualized protocols tailored to balance the heightened risk of bleeding with thromboembolic events, which are a particular concern in CA procedures. Thus, management requires a dynamic approach that considers the renal status, comorbidities, and bleeding history of each patient. Continuous adjustments and careful monitoring are essential to the personalized care needed in this high-risk group.

Scheduling and Dialysis Coordination

Coordinating CA procedures with existing dialysis schedules for patients on HD presents significant logistical challenges. Coordination is not straightforward because of the fixed nature of dialysis sessions and the need to avoid disrupting essential renal care. Additionally, CA involves fluid management, necessitating careful consideration during scheduling to prevent fluid overload. Effective coordination requires meticulous planning and close collaboration between the cardiology and nephrology teams. The aim is to align the timing of the CA with the patient’s regular dialysis schedule, ensuring that both treatments are delivered efficiently and safely without compromising the patient’s overall health and treatment efficacy.

Modalities and Procedure Considerations

The choice of CA modality in HD patients, whether radiofrequency or cryoballoon, carries distinct considerations regarding procedure specifics.³ In RF ablation, particular attention must be paid to the volume of irrigation used because excessive irrigation can lead to fluid overload, which is a significant risk factor for patients with compromised renal function. Cryoballoon ablation generally requires less irrigation volume, which can be an advantage for HD patients, but the use of contrast agents in cryoballoon procedures presents a new set of concerns, particularly in patients with renal impairment. The potential effect of contrast media on renal function must be carefully weighed against the procedural benefits. Ultimately, the choice of CA modality should be tailored to each patient’s specific circumstances, considering various procedural nuances and their implications for patients on HD.

Pharmacological Limitations

A heightened risk of adverse effects and altered pharmacokinetics in the use of antiarrhythmic drugs has historically restricted AF management options in patients with ESRD. However, the enhanced efficacy of CA procedures, together with advancements in drug therapies and their management, have provided effective alternatives for rhythm control, reducing the reliance on pharmacotherapy in many cases.

Long-Term Outcomes and Quality of Life

Beyond immediate procedural success, long-term outcomes and quality of life improvements in patients with ESRD undergoing CA have become focal points of recent research. Studies have indicated that successful ablation can significantly reduce the burden of AF and enhance the overall quality of life.^4,5 These benefits are particularly crucial in HD patients who often have multiple comorbidities and reduced quality of life owing to their renal disease. Successful ablation can alleviate some cardiac symptoms associated with AF, leading to better functional status and improved well-being.

Recent advancements in CA technology, including contact force-sensing catheters and advanced imaging for precise anatomical mapping, have significantly improved the safety and effectiveness of these procedures, particularly for patients undergoing HD.^2–8 However, a notable concern in this group is the high rate of late recurrence (LR) of AF after ablation. In this issue of the Journal, a study by Onishi et al⁹ involving 5,009 patients from the Kansai Plus Atrial Fibrillation Registry, including 67 patients on HD, sheds light on this issue. The research highlighted that HD is an independent risk factor for LR after initial CA. Notably, in patients experiencing early recurrence (ER) within 90 days post-CA, those undergoing HD had a significantly lower rate of maintaining sinus rhythm 3 years after the initial CA than non-HD patients. Conversely, in patients without ER, the difference in sinus rhythm maintenance between patients on HD and not on HD was not significant, indicating that ER is a strong predictor of LR in patients on HD. Despite these challenges, this study found that patients on HD without ER after initial CA could expect favorable outcomes. Interestingly, while the rate of sinus rhythm maintenance immediately after the first CA session was lower in patients on HD, there was no significant difference between the HD and non-HD groups in terms of the overall outcome after the final session, suggesting that effective pulmonary vein isolation (PVI) is a critical factor. These findings underscore the importance of PVI in the management of AF in patients undergoing HD. Despite the prevalence of AF in patients on HD, the overall outcomes after complete PVI did not differ significantly between the HD and non-HD groups, which suggests that successful PVI is a crucial first step in the effective management of AF, even in the challenging context of HD.

Ongoing research is essential for advancing our understanding and management of AF in patients undergoing HD. Areas such as the long-term effects of ablation on renal function, the development of less invasive or noninvasive ablation techniques, and further refinement of patient selection criteria are key research directions. Additionally, exploring the role of ablation in the broader context of holistic patient care, including the integration of lifestyle modifications and adjunctive therapies, is important to optimize patient outcomes. The landscape of CA for AF in patients undergoing HD has evolved substantially, driven by technological advancements, procedural techniques, and a deeper understanding of patient-specific challenges. These improvements have led to safer and more effective ablation procedures, offering valuable therapeutic options for the management of AF in this complex patient population. As we continue to build on these advancements, the future holds promise for further enhancing the care and quality of life of patients with AF undergoing HD.

Disclosures

Remuneration for lectures: Johnson & Johnson, Medtronic, Boston Scientific Japan, Abbott, Toray. Affiliation with Endowed Department: Medtronic, Fukuda Denshi, Japan Lifeline.

References

• 1.   Lutz PDMJ, Jurk PDRNK. Platelets in advanced chronic kidney disease: Two sides of the coin. Semin Thromb Hemost 2020; 46: 342–356, doi:10.1055/s-0040-1708841.
• 2.   Yamamoto T, Miyazaki S, Tanaka Y, Kono T, Nakata T, Mizukami A, et al. Peri-procedural anticoagulation in patients with end-stage kidney disease undergoing atrial fibrillation ablation: Results from the multicentre end-stage kidney disease-atrial fibrillation ablation registry. Europace 2023; 25: 1400–1407, doi:10.1093/europace/euad056.
• 3.   Takamiya T, Nitta J, Inaba O, Sato A, Inamura Y, Kato N, et al. Cryoballoon versus radiofrequency ablation for paroxysmal atrial fibrillation in hemodialysis patients. Heart Vessels 2020; 35: 1709–1716, doi:10.1007/s00380-020-01646-5.
• 4.   Hachisuka M, Hayashi H, Iwasaki Y, Ito N, AraiT, Kobayashi S, et al. Improvement in quality of life via catheter ablation for atrial fibrillation in patients undergoing hemodialysis therapy. CJC Open 2022; 4: 748–755, doi:10.1016/j.cjco.2022.05.009.
• 5.   Chen L, Gao H, Liang T, Zhao X. Catheter ablation for patients on hemodialysis with symptomatic atrial fibrillation. Ann Palliat Med 2022; 11: 2862–2870, doi:10.21037/apm-22-410.
• 6.   Hayashi M, Kaneko S, Shimano M, Ohashi T, Kubota R, Takeshita K, et al. Efficacy and safety of radiofrequency catheter ablation for atrial fibrillation in chronic hemodialysis patients. Nephrol Dial Transplant 2014; 29: 160–167, doi:10.1093/ndt/gft233.
• 7.   Takigawa M, Kuwahara T, Takahashi A, Kobori A, Takahashi Y, Okubo K, et al. The impact of haemodialysis on the outcomes of catheter ablation in patients with paroxysmal atrial fibrillation. EP Europace 2014; 16: 327–334, doi.org/10.1093/europace/eut230.
• 8.   Sairaku A, Yoshida Y, Kamiya H, Tatematsu Y, Nanasato M, Hirayama H, et al. Outcomes of ablation of paroxysmal atrial fibrillation in patients on chronic hemodialysis. J Cardiovasc Electrophysiol 2012; 23: 1289–1294, doi:10.1111/j.1540-8167.2012.02422.x.
• 9.   Onishi N, Kaitani K, Nakagawa Y, Kobori A, Inoue K, Kurotobi T, et al. Radiofrequency catheter ablation for atrial fibrillation patients on hemodialysis (from the Kansai Plus Atrial Fibrillation Registry): Clinical impact of early recurrence. Circ J 2024; 88: 1057–1064, doi:10.1253/circj.CJ-23-0671.